NCT03394586 is a clinical trial of Exposure to golimumab in Ulcerative Colitis, sponsored by University of Zurich.

Who is sponsoring NCT03394586?

NCT03394586 is sponsored by University of Zurich.

What drugs are being tested in NCT03394586?

Interventions in NCT03394586: Exposure to golimumab.

What condition does NCT03394586 study?

NCT03394586 studies Ulcerative Colitis, Flare Up, Symptom.

Is NCT03394586 still recruiting?

NCT03394586 is currently status unknown. Last updated 9 January 2018.

Last reviewed 2018-01-09 · How we verify

NCT03394586

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Real-world Data Regarding Treatment of Ulcerative Colitis Patients With Golimumab

Status unknown Last updated 9 January 2018

What this trial tests

trial testing Exposure to golimumab in Ulcerative Colitis in 100 participants. Status unknown.

Timeline

1 January 2018

Primary endpoint
31 December 2018

31 December 2018

Quick facts

Lead sponsor	University of Zurich
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 January 2018
Primary completion	31 December 2018
Estimated completion	31 December 2018
Sites	1 location across Switzerland

Drugs / interventions tested

Exposure to golimumab — full drug profile →

Conditions studied

Ulcerative Colitis — all drugs for Ulcerative Colitis →
Flare Up, Symptom — all drugs for Flare Up, Symptom →

Sponsor

University of Zurich

Who can join

Eligibility, any sex, with Ulcerative Colitis or Flare Up, Symptom. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

TNF inhibitors have improved treatment options for patients with inflammatory bowel disease (IBD) and three TNF inhibitors, infliximab, adalimumab and golimumab are available for treatment of ulcerative colitis in Switzerland. However, these drugs have been tested under ideal conditions in randomized controlled trials. Real-world data are needed to complement this information. It is the aim of our study to test, whether patients with ulcerative colitis can be effectively treated with golimumab in a real world setting in Switzerland. The investigators will use data from the Swiss IBD cohort study (SIBDC) in Switzerland. They will identify all SIBDC patients with UC treated with Golimumab and perform a retrospective chart review. The investigators will acquire patient reported outcomes and objective measures for inflammation at baseline, at 6-10 weeks and at 6 and 12 months after golimumab treatment. Primary endpoint will be clinical response (i.e. meaningful improvement) at 6-10 weeks. Secondary endpoints will be clinical response at 6 and 12 months and clinical remission (i.e. free of symptoms of disease).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Exposure to golimumab

Trials testing the same drug.

NCT05405465 — Effectiveness of Golimumab in Patients With Ulcerative Colitis: Results of a Real-life Study in Switzerland · completed

Other recruiting trials for Ulcerative Colitis

Currently open trials in the same condition.

NCT07185009 — A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Acti · Phase 3 · recruiting
NCT07265570 — Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) · Phase 2 · recruiting
NCT07223424 — Patient Preference for Subcutaneous vs. Intravenous Immune Therapy · Phase 2 · recruiting
NCT06405087 — A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD · Phase 3 · recruiting
NCT07184996 — An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ · Phase 3 · recruiting

Other University of Zurich trials

Trials by the same sponsor.

NCT07485699 — Soy Processing and Food Allergy · NA · not yet recruiting
NCT07516912 — Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland · not yet recruiting
NCT07473115 — Individualized Analgesia in the Intensive Care Unit With a New Pain Assessment Bundle and Protocolized Analgesia Adjustm · not yet recruiting
NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
NCT06481982 — Value of Advanced MRI Techniques in the Assessment of Endometriosis · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03394586 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Zurich
Last refreshed: 9 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03394586.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing